This content was created by Everyday Health Media on behalf of an advertiser.
More Information.
Content on this page was created by the Everyday Health Media team and is funded by an advertiser. The content conforms to Everyday Health Media’s editorial standards for accuracy, objectivity, and balance. The advertiser may select the specialty area but does not edit or approve the content.
Advances in Multiple Sclerosis
When Clinical MS Manifestations Don’t Reflect What’s Happening in the Brain
Jaime Imitola, MD, of the University of Connecticut, describes the phenomenon of when MRI findings are worse than a patient's clinical presentation. (0:47)
video
Familial MS
Is sGFAP a Dynamic New Biomarker for Disease Progression in MS?
An international team of experts certainly thinks so. Their new findings indicate that serum glial fibrillary acidic protein can predict worsening independent of relapse activity in multiple sclerosis.
In MS Patients, Sleep Affects Cognitive Function in Expected—and Unexpected—Ways
Sleep disorders, including obstructive sleep apnea, insomnia, and symptomatic sleepiness, can have negative effects on cognitive function in multiple sclerosis patients. A study examines just how insidious these effects are, and what can be done about them.
MS: The Possible Family Fallout
Jaime Imitola, MD, of the University of Connecticut, discusses the possible ramifications an MS diagnosis has on family dynamics. (2:21)
video
MS and Family Planning
Emotional Recognition in Multiple Sclerosis
Researchers compared emotional recognition in patients with secondary progressive MS versus those with relapsing-remitting MS. They found the two different MS courses have different impairments—either cognitive or mood—depending on the type of MS.
"I’ve Been Diagnosed with MS. Should I Tell Anyone?"
That’s the dilemma that many patients who learn they have multiple sclerosis are forced to confront, partly because of concerns about the negative consequences of doing so. A new study examined the behaviors associated with this issue.
A Closer Look at MS Risk in Patients Taking Anti-TNFα Agents
In a nested case-control study, Canadian investigators assessed the risk of incident MS among patients taking anti-TNFα agents for treatment of rheumatic diseases or IBD. The goal? Providing a stronger basis for informed treatment decisions.
In Patients with MS, Fatigue Slams Quality of Life
Walking ability, other physical activities, and psychological well-being are negatively impacted in patients with MS. These investigators assessed the challenges with data from the UK MS register.
Helping Patients with Multiple Sclerosis Steer a Stable Financial Course
You may not be able to change current healthcare payment systems, but a new study shows that you may be able to help your individual patients navigate their worries.
MS and Race: Does Prevalence Differ Between Groups?
MS was previously considered to be a disease that primarily affects White people, but according to a recent study this presumption does not hold.
Multiple Sclerosis, DMTs, and the Role of Specialty Pharmacists
Despite the beneficial effects of disease-modifying therapies for relapsing MS, patients often discontinue their DMTs within a few years, for reasons ranging from side effects to insurance coverage. This puts increased pressure on specialty pharmacists to jump in.
MS-Related Optic Neuritis: Is This a New Diagnostic Era?
The results of a new study found that machine learning models may one day be instrumental in evaluating patients with suspected optic neuritis related to multiple sclerosis.
In MS, Brain Atrophy is Associated With Disease Progression Independent of Relapse Activity
These investigators demonstrated that episodes of subtle disability progression independent of relapse activity (PIRA) are associated with increased brain atrophy rates in multiple sclerosis, probably reflecting ongoing diffuse neurodegenerative processes.